Should New HEPZATO Subgroup Data and Delcath’s Targeted Strategy Require Action From DCTH Investors?

Delcath Systems announced that subgroup analyses from its phase 3 FOCUS study of the FDA-approved HEPZATO KIT for unresectable metastatic uveal melanoma were published in the Journal of Cancer ...

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastati…

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...
CURE

Hepzato Kit Safe, Effective in Metastatic, Unresectable Uveal Melanoma

The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing ...
Houston Chronicle

How LinkedIn Subgroups Work

You can find over one million groups to join on LinkedIn, the social media network for professionals. Topics vary from discussions about how to think creatively to learning something new such as ...
The New England Journal of Medicine

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better ...
Morningstar

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma Delcath Systems, Inc.